Serum-based ALYGNSA immunoassay for the prostate cancer biomarker, total prostate-specific antigen (tPSA)

被引:1
作者
Mackness, Brian C. [1 ]
McDonald, Melisenda J. [1 ]
机构
[1] Univ Massachusetts Lowell, Coll Arts & Sci, Dept Chem, Biochem Program, Lowell, MA 01854 USA
基金
美国国家科学基金会;
关键词
Total prostate-specific antigen; Cancer biomarker; ALYGNSA; Serum-based; Immunoassay; DISEASE; SAMPLES;
D O I
10.1007/s00216-010-3827-0
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Prostate-specific antigen (PSA) is a serum glycoprotein overproduced by the prostate in prostate cancer (a parts per thousand yen4 ng/mL in the bloodstream). An immunoassay for total PSA (tPSA) was developed using the ALYGNSA method to enhance capture antibody orientation and a limit of detection of 0.63 ng/mL was reported, a limit 15-fold lower than a commercial tPSA ELISA assay. This ALYGNSA assay, however, was performed using only buffer-based proteins and blocking agents (Mackness et al., Anal Bioanal Chem 396:681-686, 2010). To improve the clinical application of this system, a serum-based tPSA ALYGNSA was developed employing human serum. This assay also resulted in a limit of detection of 0.63 ng/mL of tPSA protein. The findings reported here provide support for the clinical application of this assay for diagnosis, progression, treatment, and possible recurrence of prostate cancer.
引用
收藏
页码:3151 / 3154
页数:4
相关论文
共 18 条
  • [1] Biology of prostate-specific antigen
    Balk, SP
    Ko, YJ
    Bubley, GJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) : 383 - 391
  • [2] Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease - A prospective multicenter clinical trial
    Catalona, WJ
    Partin, AW
    Slawin, KM
    Brawer, MK
    Flanigan, RC
    Patel, A
    Richie, JP
    deKernion, JB
    Walsh, PC
    Scardino, PT
    Lange, PH
    Subong, ENP
    Parson, RE
    Gasior, GH
    Loveland, KG
    Southwick, PC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (19): : 1542 - 1547
  • [3] CHOURB S, 2009, HEALTH, V1, P325
  • [4] Antibody orientation enhanced by selective polymer-protein noncovalent interactions
    Clarizia, Lisa-Jo A.
    Sok, Davin
    Wei, Ming
    Mead, Joey
    Barry, Carol
    McDonald, Melisenda J.
    [J]. ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2009, 393 (05) : 1531 - 1538
  • [5] Etzioni R, 2004, CANCER EPIDEM BIOMAR, V13, P1640
  • [6] A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease
    Gray, Joe
    Chattopadhyay, Dipankar
    Beale, Gary S.
    Patman, Gillian L.
    Miele, Luca
    King, Barry P.
    Stewart, Stephen
    Hudson, Mark
    Day, Christopher P.
    Manas, Derek M.
    Reeves, Helen L.
    [J]. BMC CANCER, 2009, 9
  • [7] Direct detection of carcinoembryonic antigen autoantibodies in clinical human serum samples using a surface plasmon resonance sensor
    Ladd, Jon
    Lu, Hailing
    Taylor, Allen D.
    Goodell, Vivian
    Disis, Mary L.
    Jiang, Shaoyi
    [J]. COLLOIDS AND SURFACES B-BIOINTERFACES, 2009, 70 (01) : 1 - 6
  • [8] Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis
    Lee, Jean W.
    Hall, Michael
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2009, 877 (13): : 1259 - 1271
  • [9] Polymer-protein-enhanced fluoroimmunoassay for prostate-specific antigen
    Mackness, Brian C.
    Chourb, Sinang
    Farris, Leslie R.
    McDonald, Melisenda J.
    [J]. ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2010, 396 (02) : 681 - 686
  • [10] PROSTATE SPECIFIC ANTIGEN - A CRITICAL-ASSESSMENT OF THE MOST USEFUL TUMOR-MARKER FOR ADENOCARCINOMA OF THE PROSTATE
    OESTERLING, JE
    [J]. JOURNAL OF UROLOGY, 1991, 145 (05) : 907 - 923